Results - Announcements
RPG Life Sciences Ltd share price advanced by 5.21% to Rs 2995.65 after the company's net profit softened by 7.72% to Rs 28.22 crore, while revenue from operations improved marginally 8.15% to Rs 211.64 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, gaining 4.44%. It has inched up 5.74% over last one week and crept higher by 0.60% in last one month while the market capitalization of RPG Life Sciences Ltd has increased 14.42% and 8.26% in the same period respectively.
Profit before tax (PBT) of RPG Life Sciences Ltd stood at Rs 37.04 crore in Q3 FY26, crashing by 25.10% year-on-year, and falling 10.14% quarter-on-quarter. EBITDA came in at Rs 36 crore, rising 4.84% YoY and slipping 8.29% sequentially.
Total expenses advancing by 12.67% to Rs 178.02 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 24.1 crore, plunging by 36.04% YoY, while employee benefits expense was at Rs 44.09 crore, soaring 16.76% YoY.
For the TTM ended FY26, revenue from operations posted a slight growth of 8.28% to Rs 707.52 crore, while net profit tumbled by 37.15% to Rs 115.17 crore, compared to previous TTM. EBITDA soared by 14602% to Rs 121.59 crore, and PBT plunged by 33.79% to Rs 154.2 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 56.5 crore in FY26, as against Rs 77.86 crore in FY25.
RPG Life Sciences Ltd surged by 22.80% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 12.76% during the same period.